Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : January Effect 2001 -- Ignore unavailable to you. Want to Upgrade?

To: RockyBalboa who wrote (207)	1/21/2001 1:03:55 PM
From: RockyBalboa	Respond to of 289

There are stocks like STMP, CLRS, MAXM and several others which are at P/C < 0.5 o at least < 1 but they don't trade up as of now. That could point to more trouble lying ahead? More trouble, I must be damned. MAXM, trading halted. quote.yahoo.com Maxim says FDA rejects skin cancer drug application SAN DIEGO, Jan 19 (Reuters) - Maxim Pharmaceuticals (NasdaqNM:MAXM - news) said it received on Friday a nonapprovable letter from the U.S. Food and Drug Administration (FDA) relating to the company's application for its advanced skin cancer drug. The FDA stated that the U.S. Phase 3 clinical trial forming the basis of the application for Celpene -- the company previously called the drug Maxamine -- would not be adequate as a single study to support approval, the San Diego company said in a statement. Maxim said it will meet with the FDA to develop a clinical strategy to support the approvability of the drug in combination with other treatment in patients with advanced metastatic melanoma with liver metastases. In December, an FDA advisory committee recommended rejection of the company's application, sendings its shares down some 30 percent to just over $9. On Friday, Maxim's shares were down $1-7/16 at $7-5/16.